

### Vaccinia Virus, Modified Vaccinia Ankara (MVA)

#### Catalog No. NR-1

This reagent is the tangible property of the U.S. Government.

#### For research use only. Not for human use.

#### Contributor:

Linda S. Wyatt, Ph.D. and Bernard Moss, M.D., Ph.D., Chief, Laboratory of Viral Diseases, Division of Intramural Research, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland

#### Product Description:

Virus Classification: *Poxviridae, Orthopoxvirus*

Agent: Vaccinia virus (VACV)

Strain: Modified VACV Ankara (MVA)

Source: NIAID, NIH

Comments: The early passage history of MVA is complex.<sup>1</sup> The complete genomic sequence of MVA has been determined (GenBank: U94848).<sup>2</sup>

MVA is a highly attenuated strain of vaccinia virus<sup>3</sup> and does not appear to replicate in most mammalian cells. Some experts feel MVA can be handled safely by trained personnel without the need for vaccination.

#### Material Provided:

Each vial contains approximately 1 mL of cell lysate and supernatant from chicken embryo fibroblast (SL-29) cells infected with VACV, MVA.

#### Packaging/Storage:

NR-1 was packaged aseptically, in screw-capped plastic cryovials. The product is provided frozen and should be stored at -60°C or colder immediately upon arrival. For long-term storage, the vapor phase of a liquid nitrogen freezer is recommended. Freeze-thaw cycles should be avoided.

#### Growth Conditions:

Host: SL-29 cells (ATCC® CRL-1590™)

Growth Medium: Dulbecco's Modified Eagle's Medium supplemented with 5% fetal bovine serum and 5% tryptose phosphate broth, or equivalent (lot-specific details are on the Certificate of Analysis)

Infection: Cells should be 80 to 90% confluent (not 100% confluent)

Incubation: 3 to 5 days at 37°C and 5% CO<sub>2</sub>

Cytopathic Effect: Rounding of cells and cell lysis

#### Citation:

Acknowledgment for publications should read "The following reagent was obtained through the NIH Biodefense and Emerging Infections Research Resources Repository, NIAID, NIH: Vaccinia Virus, Modified Vaccinia Ankara (MVA), NR-1."

#### Biosafety Level: 2

Appropriate safety procedures should always be used with this material. Laboratory safety is discussed in the following

publication: U.S. Department of Health and Human Services, Public Health Service, Centers for Disease Control and Prevention, and National Institutes of Health. Biosafety in Microbiological and Biomedical Laboratories. 4th ed. Washington, DC: U.S. Government Printing Office, 1999. HHS Publication No. (CDC) 93-8395. This text is available online at [www.cdc.gov/od/ohs/biosfty/bmbl4/bmbl4toc.htm](http://www.cdc.gov/od/ohs/biosfty/bmbl4/bmbl4toc.htm).

#### Disclaimers:

You are authorized to use this product for research use only. It is not intended for human or animal use.

Use of this product is subject to the terms and conditions of the BEI Resources Material Transfer Agreement (MTA). The MTA is available on our Web site at [www.beiresources.org](http://www.beiresources.org).

While BEI Resources uses reasonable efforts to include accurate and up-to-date information on this product sheet, neither ATCC® nor the U.S. Government make any warranties or representations as to its accuracy. Citations from scientific literature and patents are provided for informational purposes only. Neither ATCC® nor the U.S. Government warrants that such information has been confirmed to be accurate.

This product is sent with the condition that you are responsible for its safe storage, handling, use and disposal. ATCC® and the U.S. Government are not liable for any damages or injuries arising from receipt and/or use of this product. While reasonable effort is made to ensure authenticity and reliability of materials on deposit, the U.S. Government, ATCC®, their suppliers and contributors to BEI Resources are not liable for damages arising from the misidentification or misrepresentation of products.

#### Use Restrictions:

**This material is distributed for internal research, non-commercial purposes only.** This material, its product or its derivatives may not be distributed to third parties. Except as performed under a U.S. Government contract, individuals contemplating commercial use of the material, its products or its derivatives must contact the contributor to negotiate a license. U.S. Government contractors may need a license before first commercial sale.

#### References:

1. Mayr, A., V. Hochstein-Mintzel, and H. Stickl. "Passage History, Properties, and Applicability of the Attenuated Vaccinia Virus Strain MVA." Infection 3 (1975): 6–14.
2. Antoine, G., F. Scheifflinger, F. Dorner, and F. G. Falkner. "The Complete Genomic Sequence of the Modified Vaccinia Ankara Strain: Comparison with Other Orthopoxviruses." Virology 244 (1998): 365–396. PubMed: 9601507. GenBank: U94848.
3. Wyatt, L. S., et al. "Marker Rescue of the Host Range Restriction Defects of Modified Vaccinia Virus Ankara." Virology 251 (1998): 334–342. PubMed: 9837798.

ATCC® is a trademark of the American Type Culture Collection.